Skip to main content

Wysa

Category: AI in Healthcare

An AI-driven mental health platform that provides 24/7 anonymous conversational support using evidence-based techniques like CBT, DBT, and meditation. Wysa was founded in 2015. The company is led by Jo Aggarwal. Based in Boston, USA. Team size: 150+. Total funding raised: $30.5M. Latest round: Series B. Key investors include HealthQuad, British International Investment (BII), W Health Ventures, Kae Capital, pi Ventures, Google Assistant Investment Program.

Founded
2015
Headquarters
Boston, USA
Team size
150+
Total funding
$30.5M

Value proposition

Provides immediate, stigma-free, and scalable mental health support that bridges the gap between self-care and clinical therapy, improving access while reducing costs for payers.

Products and solutions

Wysa AI Coach (Conversational Chatbot), Wysa for Employers (Enterprise Wellness Platform), Wysa for Healthcare (Clinical integration for providers), Human-led Coaching (Text-based professional support), Wysa for Chronic Pain (FDA-designated digital therapeutic)

Unique value

Wysa utilizes a 'safety-first' hybrid AI model that combines empathetic conversational AI with strict clinical guardrails, ensuring it can detect and escalate crisis situations unlike standard LLMs.

Target customer

Global enterprises (HR/Employee Benefits), healthcare providers, health insurance companies, and individual B2C consumers.

Industries served

Healthcare & Digital Health, Corporate Wellness / Human Resources, Insurance (Payers), Public Health & Government

Technology advantage

Proprietary conversational engine trained on over 500 million messages with peer-reviewed clinical validation; it is one of the few AI mental health tools to receive FDA Breakthrough Device status.

How they differentiate

Wysa differentiates through its 'safety-first' hybrid AI model and clinical rigor. Unlike generic LLMs, it uses a proprietary conversational engine with strict clinical guardrails and is one of the few AI tools to receive FDA Breakthrough Device Designation (specifically for chronic pain). It focuses on 'triage,' identifying high-risk users and escalating them to human professionals.

Main competitors

Woebot Health, Youper, Ginger (Headspace Health), BetterHelp

Key partnerships

National Health Service (NHS), UK, Ministry of Health, Singapore, Travelers Insurance, Aetna International, Google Assistant Investment Program, HealthQuad and British International Investment (BII)

Notable customers

National Health Service (NHS) UK, Ministry of Health Singapore, Travelers Insurance, Aetna International, Accenture

Major milestones

Received FDA Breakthrough Device Designation for AI-led CBT for chronic pain in 2021, Closed $20M Series B funding round in July 2022, Selected as one of the top 20 startups for the India AI Impact Summit in 2024, Achieved over 500 million conversations with clinical validation

Growth metrics

Supports over 6.5 million users across 95 countries; processed over 500 million messages; estimated ARR between $5M - $10M.

Market positioning

Enterprise-grade AI mental health coach and triage platform

Geographic focus

North America, United Kingdom, India, and Southeast Asia (Singapore)

Patents and IP

Proprietary IP related to its conversational AI architecture and clinical safety protocols; holds US patents for systems and methods providing mental health support via conversational agents.

About Jo Aggarwal

Jo Aggarwal is the Co-founder and CEO of Wysa. She previously served as the Managing Director of Pearson Learning Solutions in the UK and was the Founding Director for Technology & Innovation for Silatech, a UN-backed foundation. Her career began in the Tata Administrative Service (TAS) leadership cadre, and she has held leadership roles at Tata Interactive Systems and served as an expert advisor to McKinsey & Co.

Official website: